Follow the Money: Brain-Computer Retinal Implant, Expansion of Alzheimer’s Platform, Migraine Therapies

$230M: Series C for Brain-Computer Retinal Implant 

Science Corporation closed an oversubscribed $230 million Series C financing round. The funds will accelerate the commercialization of Science’s brain-computer interface retinal implant, PRIMA. In clinical trials, PRIMA was the only treatment to successfully restore former vision to patients blinded by late-stage macular degeneration. The PRIMA trial results were featured in The New England Journal of Medicine and on the cover of Time. 

$130M: Series A for Anti-PACAP Therapies for Migraine 

Slate Medicines announced the closing of a $130 million Series A financing, alongside the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody licensed from DartsBio Pharmaceuticals (Guangdong). SLTE-1009, also known as DS009, is a monoclonal antibody targeting PACAP for the prevention of migraine and other headache disorders. PACAP has emerged as a clinically validated target distinct from CGRP, offering potential benefits for patients underserved by current preventive therapies. 

$105M: Series C for Alzheimer’s Platform Advancement 

Cognito Therapeutics announced the final closing of its oversubscribed $105 million Series C funding. The financing will help Cognito advance toward pivotal data readout, regulatory submission, and commercial launch, while supporting continued clinical development of the company’s Spectris platform and expansion of launch readiness efforts ahead of anticipated market entry in 2027. Spectris is an investigational physician-prescribed, at-home therapeutic platform designed to evoke coordinated neural activity, across interconnected networks, through non-invasive visual and auditory stimulation. The proceeds will also support advancement of the Spectris platform into additional neurodegenerative indications through their network of brain health collaboratories beginning with WVU Rockefeller Neuroscience Institute.

$100M: Series A for Parkinson’s and Dystonia Drug 

Vima Therapeutics extended its Series A financing by $40 million to advance its investigational Parkinson’s and dystonia pill, VIM0423. This brings the total funding round to $100 million. With the funds, the company will conduct two phase 2 clinical trials on the selective muscarinic cholinergic receptor antagonist in dystonia and Parkinson’s disease. VIM0423 is designed to selectively target specific muscarinic receptors found in the brain, thus reducing off-target effects commonly associated with the class, such as diarrhea and other gastrointestinal issues. Vima has already begun its phase 2 study on VIM0423 in dystonia and hopes to begin its Parkinson’s study in mid-2026. 

$77.5M: Series A for First-in-Class Treatment for Kidney Disease 

R1 announced its launch with an oversubscribed $77.5 million Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals. Proceeds from the Series A financing will fund R1's global development program of AP306 in partnership with Alebund, including a phase 2b study planned to start later this year. AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease. 

$60M: Series B for Precision Genetic Medicines 

BreezeBio, formerly known as GenEdit, announced the closing of $60 million in Series B financing to advance its first internal therapeutic programs toward the clinic and to continue expansion of the company’s NanoGalaxy delivery platform. The company’s lead therapeutic candidate, BRZ-101, is a novel immune modulation therapy designed to restore tolerance in type 1 diabetes. The therapy delivers autoantigens encoded by mRNA and tolerogenic co-factors to antigen-presenting cells, which in turn present the antigens to T cells in the context of tolerance. NanoGalaxy has demonstrated targeted delivery to the immune, cardiac, pulmonary, and central nervous systems based on the physiochemical properties of the polymers that encapsulate the payloads and form the nanoparticles.  

$50M: Series A for T-Cell Engager for Autoimmune Disease 

Prolium launched with a $50 million Series A Financing to develop PRO-203, a potential best-in-class CD20xCD3 T-cell engager, for severe autoimmune disease. The company has started dosing healthy volunteers in an ongoing single ascending dose study of PRO-203 and expects to initiate a multinational phase 1/2 study of PRO-203 in systemic sclerosis in Q2 2026. Additionally, five patients with treatment-refractory, advanced systemic lupus erythematosus, all of whom also have lupus nephritis, have been treated with PRO-203 in an investigator-initiated study. Prolium plans to initiate further clinical studies this year in additional severe autoimmune diseases that are driven predominantly by aberrant B-cells. 

$45M: Series B for Advancing Macrocyclic Peptide Therapeutics 

Unnatural Products announced the closing of a $45 million Series B financing. The funding will support development of the company’s proprietary drug discovery platform and advance its pipeline of macrocyclic peptide therapeutics designed to address historically difficult-to-drug or “undruggable” targets. Unnatural Products has developed an integrated discovery platform capable of repeatedly engineering synthetic macrocyclic peptides at scale. The company’s platform integrates advanced computational design, automated chemistry, and high-throughput biological testing to rapidly move from initial discovery hits to optimized drug candidates. The company is also advancing a pipeline of macrocyclic peptide therapeutics for the treatment of cardiometabolic, inflammatory, and immunological diseases. 

$28M: Series E for Minimally Invasive Neurosurgery 

Monteris Medical closed $28 million in Series E equity financing. The funds will support the company's technology innovation program and other growth initiatives, such as expanding the company's U.S. commercial footprint. The financing will also accelerate Monteris' other growth initiatives in technological development, clinical research, and geographic expansion. Monteris Medical develops and markets innovative MR‑guided laser ablation systems that enable minimally invasive, robotically controlled brain surgery, often referred to as laser ablation, laser interstitial thermal therapy, or stereotactic laser ablation. 

$24M: Series A for First Financial Intelligence Platform for Life Sciences 

Condor Software closed a $24 million Series A funding round. While AI is rapidly reshaping how drugs are discovered and developed, the financial infrastructure that determines which programs get funded still runs on spreadsheets that require manual reconciliation across disconnected CRO portals, ERP systems, and accounting tools. Condor’s AI-powered Financial Intelligence Platform addresses this by automatically consolidating clinical, operational, and financial data and enabling life sciences teams to move faster, save money, and operate confidently. Condor's platform is built on proprietary clinical and financial ontologies that map the relationships between trial protocols, site-level activity, vendor contracts, and accounting rules. The three core modules are connect, compass, and copilot. 

$22M: Series C for Commercial Launch of Spinal Cord Injury Treatment 

ANEUVO closed a Series C funding round of $22 million. Proceeds will be used to execute commercial launch in approved markets and sales expansion, scale manufacturing and quality systems to meet global demand, advance U.S regulatory activities for ExaStim, and continue clinical and real-world evidence generation to drive market adoption. The ExaStim Stimulation System delivers personalized spinal cord stimulation, non-invasively, designed to support functional neurorehabilitation for patients with paralysis due to spinal cord injury. 

$13M: Series A for Drug Candidate for MASH 

MAX BioPharma, in collaboration with Technomark, raised a $13 million Series A financing. Technomark and MAX BioPharma announced their collaboration in the development of MAX BioPharma's oxysterol drug candidate, Oxy210, for targeting metabolic dysfunction-associated steatohepatitis (MASH). Technomark is investing in MAX BioPharma to initiate and complete a phase 1a/1b first-in-human study and invites aligned investors from the industry to join this opportunity. 

$6.5M: Series C for Expansion of AI Imaging Tools 

Brainomix announced a $6.5 million extension to its Series C financing, in addition to the $18.9 million secured last year, bringing the total round to $25.4 million. With existing operations in the U.S. and an extensive portfolio of FDA-cleared AI imaging solutions, the additional capital will enable Brainomix to further expand in the U.S. market as the company advances deployment of its AI imaging platforms, Brainomix 360 Stroke and e-Lung, across multiple hospitals.

$3.9M: Seed Financing for RNA-Seq Kits for Primary Drug Screening and Toxicology 

Alithea Genomics closed its seed financing round with an additional $3.9 million, totaling to $8.9 million. The proceeds will be used primarily to accelerate commercialization of its new 1536‑well MERCURIUS DRUG-seq kits unlocking greater potential of using cell transcriptomics in primary drug screening and exploratory toxicology. These applications, previously out of reach due to cost and throughput constraints, can now be addressed by scaling 3′RNA‑seq library preparation to 1,536 samples. Alithea will also invest the proceeds in accelerating new technology development and building proprietary transcriptomic data assets to fuel the industry's AI/ML initiatives. 

$3.4M: Series A for Bladder Cancer Treatment 

Combat Medical raised $3.4 million in the first close of a Series A financing to advance its hyperthermic intravesical chemotherapy treatment, HIVEC, through phase 3 clinical trials and toward FDA registration. The funding will be used to further fund the ongoing pivotal FDA registration trial, HIVEC HEAT, to investigate the effectiveness of the company’s HIVEC treatment of BCG unresponsive non-muscle-invasive bladder cancer. The primary objective is to generate phase 3 clinical data as evidence that Combat’s patented HIVEC treatment is an effective, safe, and tolerable alternative to the current standard of care, which is radical cystectomy. Combat will use future financing to complete FDA registration, growing operations to scale, expanding its existing clinical programs for advanced bladder cancer (HIVEC) and peritoneal cancer (HIPEC), with a focus on US market entry.

$2.1M: Financing for Liquid Biopsy 

University of Edinburgh spin-out BIOCAPTIVA raised $2.1 million in a new funding round and launched its first product in the U.S. BIOCAPTIVA is a novel magnetic bead technology is designed to solve one of liquid biopsy’s biggest bottlenecks: preparing blood samples for cancer research and diagnostics. By improving how cell-free DNA is captured from blood, the technology aims to make liquid biopsy testing more reliable, scalable, and accessible. The company's patented msX platform extracts DNA directly from whole blood without the need for centrifuges or additional reagents, delivering higher quality samples with simpler, faster processing.